BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
ZALTRAP (ziv-aflibercept) by Sanofi is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2012.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZALTRAP (ziv-aflibercept) is a fusion protein that acts as a VEGF inhibitor, blocking vascular endothelial growth factor to inhibit tumor angiogenesis. It is administered intravenously and is indicated for metastatic colorectal cancer in combination with 5-FU-based chemotherapy. The drug works by sequestering VEGF, preventing its interaction with endothelial growth factor receptors on tumor vasculature.
Peak
ZALTRAP is in peak lifecycle phase with moderate competitive pressure (30%), indicating a stable but challenged market position that may support steady-state commercial teams rather than growth-phase hiring.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Started Nov 2024
32 enrolled
Metastatic Uveal Melanoma
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
Started Nov 2014
0Colorectal CancerMetastatic Colorectal Cancer
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
Started Mar 2014
0Metastatic Colorectal Cancer
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Started Feb 2014
0Adenocarcinoma of the ColonAdenocarcinoma of the Rectum
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Started Oct 2012
48 enrolled
Solid Tumors
Worked on ZALTRAP at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.